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Derivatization of a variety of peptides by a method known to enhance anhydride formation is
demonstrated by mass spectrometry to yield ions that have elemental composition and
fragmentation properties identical to [b(n1)  OH  H]
 ions formed by gas-phase
rearrangement and fragmentation. The [b(n1)  OH  H]
 ions formed by gas-phase
rearrangement and fragmentation and the solution-phase [b(n1)  OH  H]
 ion structural
analogs formed by derivatization chemistry show two different forms of dissociation using
multiple-collision CAD in a quadrupole ion trap and unimolecular decomposition in a
TOF-TOF; one group yields identical product ions as a truncated form of the peptide with a
free C-terminal carboxylic acid and fragments at the same activation energy; the other group
fragments differently from the truncated peptide, being more resistant to fragmentation than
the truncated peptide and yielding primarily the [b(n2) OHH]
 product ion. Nonergodic
electron capture dissociation MS/MS suggests that any structural differences between the
specific-fragmenting [b(n1)  OH  H]
 ions and the truncated peptide is at the C-terminus
of the peptide. The specific-fragmentation can be readily observed by MSn experiments to
occur in an iterative fashion, suggesting that the C-terminal structure of the original [b(n1) 
OH  H] ion is maintained after subsequent rearrangement and fragmentation events in
peptides which fragment specifically. A mechanism for the formation of specific-fragmenting
and nonspecific-fragmenting [b(n1)OHH]
 ions is proposed. (J Am Soc Mass Spectrom
2005, 16, 607–621) © 2005 American Society for Mass Spectrometry Tandem mass spectrometry is a popular tool forthe characterization of the primary structure ofpeptides [1]. Much effort has been directed to-
ward the elucidation of the mechanisms of peptide
fragmentation in the gas phase, and a number of
reviews on the subject are available [2– 4]. Some details
about the mechanism of fragmentation and the struc-
tures of the fragmentation products have been eluci-
dated [5–9]. For the past fifteen years, considerable
effort has gone into the understanding of the structure
peptide rearrangement ions and the mechanisms that
drive these rearrangements [10 –18]. One of the major
areas of interest has been the [b(n1)  OH  Cat]
 ion,
which has been observed in a variety of peptides with a
variety of cations using a variety of different ionization
techniques and mass analyzers [12–14, 16 –23]. Under-
standing the structure of these rearrangement ions and
their mechanisms of formation is important for the
analysis of peptide tandem mass spectra, as well as for
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fragmentation.
Isotopic labeling studies of the [b(n1)  OH  H]

ion of bradykinin showed that the ion retains the
C-terminal oxygen atom, while losing the rest of the
C-terminal residue. Based on this result, as well as on a
fragmentation study of the [b(n1)  OH  H]
 ion of
bradykinin compared with that of des-Arg9-bradykinin,
the structure of the [b(n1)  OH  H]
 ion was
hypothesized to be identical to that of the truncated
peptide, i.e., a free acid C-terminus [12]. Multiple
groups have proposed a mechanism for the formation
of the [b(n1)  OH  H]
 that involves the initial
formation of a seven-membered hydrogen-bonded ring
at the neutral C-terminus, followed by collapse into a
five-membered cyclic anhydride, which then results in
loss of the C-terminal amino acid residue with retention
of the original C-terminal oxygen at the new C-terminal
free acid (Scheme 1) [12, 13]. Two important features of
this mechanism should be noted—the initial formation
of a five-membered cyclic anhydride and the free car-
boxylic acid C-terminus of the end product.
Recently, Farrugia and O’Hair reported the results
of experimentation and computational modeling of
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dipeptides [17]. Their work strongly suggests that the
rearrangement in these peptides to form the [b(n1) 
OH  H] ion goes through a five-membered cyclic
intermediate (this time initiated from zwitterions at
the N- and C-termini as opposed to the neutral
termini proposed earlier) that then becomes a linear
anhydride, the actual species that leads to fragment
ions (Scheme 2). Once again, the formation of the
five-membered cyclic anhydride is a key step in the
rearrangement process. Feng et al. suggest in their
studies of dipeptide-metal ion complexes that the
resulting [b(n1)  OH  M]
 fragments have free
carboxylic acid C-termini [16], and Farrugia and
O’Hair support this conclusion in their report [17].
All mechanisms proposed thus far result in a [b(n1)
 OHH] ion with a free acid C-terminus. However,
an earlier report by Thorne and Gaskell examining the
fragmentation characteristics of the [b(n1) OHH]

ion of angiotensin III showed that the peptide did not
fragment in a standard manner. In fact, the only signif-
icant fragmentation product in the MS3 fragmentation
of the [b(n1)OHH]
 ion is the [b(n2)OHH]

ion [19]. Thorne and Gaskell suggested that this frag-
mentation pattern may be analogous to that noted for
metal-cationized peptides [20]; however, it was never
explained why the [b(n1)  OH  H]
 ion of angio-
tensin III fragmented only to the [b(n2)  OH  H]

ion, while the [b(n1)  OH  H]
 ion of bradykinin
fragmented nonspecifically.
In order to test the proposed mechanisms for the
fragmentation events involved in the formation of
[b(n1)  OH  H]
 ions, a method was developed to
synthesize structures that have elemental compositions
and fragmentation characteristics identical to those of
[b(n1)  OH  H]
 ions formed by gas-phase rear-
rangement and fragmentation. The chemistry that
yields such an analog should give significant insights
into the structure of the [b(n1)  OH  H]
 ion. In
addition, the ability to make peptide analogs that are
ScSchemestructurally identical to [b(n1)OHH]
 ions should
allow a variety of analytical techniques, such as NMR
and FT-IR, to be brought to bear in studying the
structure of these ions. The fragmentation properties
and elemental composition of these solution-phase
products (as well as their gas-phase analogs) were then
compared to peptides lacking the C-terminal residue to
determine if the [b(n1)  OH  H]
 product ions have
the same structure as the truncated peptide with a free
C-terminal carboxylic acid as previously proposed [12,
13, 16, 17].
Experimental
All peptides used were obtained from Sigma-Aldrich
(St. Louis, MO) except for LWMRFA, des-Arg9-bradyki-
nin, and des-Leu10-angiotensin I (Bachem Bioscience,
King of Prussia, PA) and used without further purifi-
cation. All reagents were obtained from Sigma-Aldrich
and used without further purification unless otherwise
noted.
Solution-Phase Formation of [b(n1)  OH  H]

Ion Structural Analogs
Solution-phase [b(n1)  OH  H]
 ion structural
analogs (hereafter termed [b(n1)  OH  H]S
 ions)
were generated by modification of the protocol of
Hardeman et al. for formation of C-terminal oxazo-
linones [24]. Peptides were weighed out and suspended
at a concentration of 0.185 mg peptide/ml in acetic
anhydride (AcAn) with 7.4% trifluoroacetic acid (Pierce
Biotechnology, Rockford, IL). The peptide mixture was
heated at 55 ° C for 15 to 25 minutes with gentle mixing.
Following the incubation, the solution was dried to
completeness by vacuum centrifuge and resuspended
in acetonitrile with 0.1% formic acid for mass spectro-
metric analysis. For formation of acetylated peptides for
comparison of gas-phase [b(n1)  OH  H]
 ions by
12
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oroacetic acid (TFA) was used. No solution-phase
[b(n1)  OH  H]
 ion structural analogs were de-
tected in the absence of TFA in the reaction.
MALDI-TOF-TOF Mass Spectrometry
All matrix assisted laser desorption ionization-time of
flight-time of flight (MALDI-TOF-TOF) spectra were
obtained on an Applied Biosystems (Foster City, CA)
4700 Proteomics Analyzer instrument. A spot of 0.2 l
of a 33% saturated solution of recrystallized -cyano-4-
hydroxycinnamic acid in 50% methanol, 50% water
with 0.1% formic acid was spotted onto a stainless steel
target. A 0.2 l spot of peptide was added to the matrix
droplet and allowed to cocrystallize. The MALDI-TOF-
TOF instrument was operated in the positive ionization,
reflector mode. Tandem mass spectrometry (MS/MS)
spectra were obtained by post-source decay with the
collision cell at background pressure (1.5 108 torr),
and a 1 kV ion acceleration voltage. All MS/MS spectra
used for direct comparison were taken under the exact
same conditions at approximately the same time in
order to maximize experimental comparability.
MALDI-FT-ICR Mass Spectrometry
All Fourier transform-ion cyclotron resonance (FT-ICR)
mass spectrometry was performed using a 9.4 T, ac-
tively shielded IonSpec FTMS (Lake Forest, CA).
MALDI-FT-ICR transient acquisitions were per-
formed in the broadband mode. Matrix was prepared
by adding 150 mg of 2,5-dihydroxybenzoic acid (Sigma-
Aldrich) to 1 ml of a solution of 50% methanol
(Mallinckrodt Laboratory Chemicals, Phillipsburg, NJ)
and 50% deionized water filtered in-house. Matrix
solution (0.3 l) was pipetted onto the stainless steel
target. Peptide solution (0.3 l) was pipetted on top of
the still-wet matrix droplet and allowed to cocrystallize.
The sample was irradiated with a Nd:YAG laser at 355
nm. Nitrogen was pulsed in to the analyzer cell to cool
the ions prior to analysis, and a delay of 8 s was used to
allow the analyzer cell to pump down to a pressure of
8 1010 torr prior to signal acquisition. Spectra were
internally calibrated, resulting in a mass error less than
2 ppm. Elemental composition analyses were per-
formed using the IonSpec Elemental Composition pack-
age. Between 2 and 30 spectra were obtained and
averaged, depending on the signal intensity of the
ion(s) of interest.
ESI-FT-ICR Electron Capture Dissociation
Tandem Mass Spectrometry
A nanoelectrospray source (Micromass Milford, MA)
was used in all ESI-FT-ICR experiments. Analyte was
dissolved in acetonitrile with 1% formic acid was in-
fused by syringe pump at a flow rate of 500 nl/min,with a probe voltage of 3.8 kV. Ions were accumulated
in an external hexapole [25] for a period of 3 s before
injection into the analyzer cell. Electron capture disso-
ciation (ECD) analysis was performed by a method
similar to those previously reported [26, 27]. Ions of
interest for ECD analysis were isolated in the analyzer
cell. A voltage of 4.5 V was applied to a dispenser
cathode for the duration of the experiment. A voltage of
0.56 V was applied opposite the analyzer cell to force
the electrons into proximity with the analyte ions. A
total of ten scans were averaged for each spectrum, with
256 K data points collected across a 256 ms transient.
ESI-QIT Mass Spectrometry
All ESI-quadrupole ion trap (QIT) spectra were ob-
tained using an Agilent Technologies (Palo Alto, CA)
LC/MSD Trap XCT mass spectrometer operated in the
positive ion mode at a flow rate of 2 l/min. The ESI
probe was held at ground potential, while the capillary
was operated at3.5 kV, and helium bath gas was used
for collision in all collisionally activated dissociation
(CAD) MS/MS experiments at a pressure of 8  106
torr. For all CAD MS/MS experiments, the SmartFrag
option was turned off. A fragmentation delay of 20 ms,
a fragmentation time of 40 ms, and an m/z precursor
isolation width of 10m/zwere used for fragmentation of
angiotensin I analogs; a fragmentation delay of 0 ms, a
fragmentation time of 40 ms, and an m/z precursor
isolation width of 10m/zwere used for fragmentation of
bradykinin analogs. Instrument parameters remained
identical for all angiotensin analog experiments; like-
wise, all instrument settings for the bradykinin analog
experiments were identical.
Results and Discussion
In order to generate solution-phase structural analogs
to [b(n1)  OH  H]
 ions by solution-phase chemis-
try, a modification of a method for the generation of
C-terminal oxazolinones [24] was utilized. A MALDI-
TOF spectrum of one such reaction using Ile7 angioten-
sin III (peptide sequence RVYIHPI) is shown in Figure
1. The loss of 113 Da from the initial reactant mass,
along with various acetylations [Ac] and/or trifluoro-
acetylations [F3Ac], explain all major ions in the spec-
trum. Also, the ions of m/z 826, 868, 880, and 922 all
fragmented in a similar manner, resulting primarily in a
loss of 97 Da (described in detail below), while the ions
of m/z 993 and 1035 yielded b- and y-type fragment ions
consistent with Ile7 angiotensin III. These data suggest
that the four ions of m/z 826, 868, 880, and 922 are
structurally related. The ions of m/z 944 and 960 also
fragmented to yield primarily a loss of 97 Da; however,
these ions correspond to sodiated and potassiated ions
which are known to undergo metal-induced fragmen-
tation/rearrangement reactions [14, 16, 22, 23]. The ion
corresponding in mass to the nonacetylated [b6OH
H]S
 analog of Ile7 angiotensin III was not present in
610 SHARP AND TOMER J Am Soc Mass Spectrom 2005, 16, 607–621sufficient abundance to isolate and fragment by MS/
MS. In order to ensure that the observed ions were not
products of in-source fragmentation, the MALDI-TOF
experiment was repeated under the same conditions for
untreated Ile7 angiotensin III peptide and the peptide
treated only with acetic anhydride, which leads to
extensive acetylation. In both cases, ions corresponding
Figure 1. MALDI-TOF spectrum of products
Abundant ions matching the mass of acetylated
tentatively labeled as [b6  OH  H]S
 ions. Pre
OH  H]S
 ion.
Table 1. Exact mass calculations for observed solution-phase [b
Observed m/z  868.4666  0.002 Observed m/z 
Number of Fluorines  0 Number of
m/z Delta m/z Formula m/z Delta
868.46673 0.00013 H62C25O15N19 880.42739 0.00
868.46674 0.00014 H68C26O20N12 880.42740 0.00
868.46624 0.00036 H72C41O19 880.42741 0.00
868.46623 0.00037 H66C40O14N7 880.42689 0.00
868.46622 0.00038 H60C39O9N14 880.42688 0.00
868.46706 0.00046 H60C55O4N6 880.42657 0.00
868.46572 0.00088 H64C54O8N2 880.42790 0.00
868.46571 0.00089 H58C53O3N9 880.42791 0.00
868.46756 0.00096 H56C40O5N18 880.42822 0.00
868.46757 0.00097 H62C41O10N11 880.42606 0.00
868.46757 0.00097 H68C42O15N4 880.42606 0.00
868.46540 0.00120 H66C24O19N15 880.42605 0.00
868.46808 0.00148 H64C27O16N16 880.42873 0.00
868.46489 0.00171 H70C39O18N3 880.42873 0.00
868.46489 0.00171 H64C38O13N10 880.42874 0.00
868.46488 0.00172 H58C37O8N17 880.42555 0.00
868.46839 0.00179 H56C56N10 880.42554 0.00
868.46840 0.00180 H62C57O5N3 880.42522 0.00198to a loss of isoleucine were not detected (data not
shown).
In order to verify that the masses of the solution-
phase reaction products measured here are indeed
indicative of loss of Ile from various acetylated and/or
trifluoroacetylated starting material, exact mass mea-
surements of the reaction products were acquired using
7 angiotensin III from the AcAn:TFA reaction.
trifluoroacetylated peptide minus isoleucine are
arely above the noise is the unacetylated [b6 
 OH  H]s
 ion structural analogs
.4272  0.002 Observed m/z  922.4384  0.002
ines  3 Number of Fluorines  3
Formula m/z Delta m/z Formula
H55C37O8N14F3 922.43847 0.00007 H59C25O15N19F
3
H61C38O13N7F3 922.43847 0.00007 H65C26O20N12F
3
H67C39O18F3 922.43879 0.00039 H57C55O4N6F3
H59C52O7N2F3 922.43797 0.00043 H69C41O19F3
H53C51O2N9F3 922.43796 0.00044 H63C40O14N7F3
H61C22O18N15F3 922.43796 0.00044 H57C39O9N14F3
H57C23O14N19F3 922.43929 0.00089 H53C40O5N18F3
H63C24O19N12F3 922.43930 0.00090 H59C41O10N11F3
H55C53O3N6F3 922.43931 0.00091 H65C42O15N4F3
H65C37O17N3F3 922.43745 0.00095 H61C54O8N2F3
H59C36O12N10F3 922.43745 0.00095 H55C53O3N9F3
H53C35O7N17F3 922.43713 0.00127 H63C24O19N15F3
H51C38O4N18F3 922.43981 0.00141 H61C27O16N16F3
H57C39O9N11F3 922.44013 0.00173 H53C56N10F3
H63C40O14N4F3 922.44013 0.00173 H59C57O5N3F3
H57C50O6N5F3 922.43663 0.00177 H67C39O18N3F3
H51C49ON12F3 922.43662 0.00178 H61C38O13N10F3of Ile
and
sent b(n1)
880
Fluor
m/z
019
020
021
031
032
063
070
071
102
114
114
115
153
153
154
165
166H59C20O17N18F3 922.43661 0.00179 H55C37O8N17F3
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tal composition analysis of three protonated molecules
suspected to be attributable to the presence of starting
material with various acetylations and/or trifluoro-
acetylations and the loss of the C-terminal Ile residue.
The elemental composition search parameters used
were 1 to 100 carbon, hydrogen, oxygen, and nitrogen
atoms, and 0 to 9 fluorine atoms (double bond equiva-
lents were disregarded to allow for the broadest prac-
tical search). All results that contained fluorine atoms
not in a multiple of three were excluded. For the three
measured masses examined, a theoretical mass matched
the measured mass that was consistent with a shift from
the mass of the parent peptide minus the C-terminal Ile
(C37H58N11O8) plus (1) two acetylations (C4H4O2), (2)
one trifluoroacetylation (H, C2F3O), or (3) one acet-
ylation and one trifluoroacetylation (C4HF3O2). In
order to verify the results of the elemental composition
analysis, the solution-phase reaction was performed
using trichloroacetic acid in place of trifluoroacetic acid,
resulting in trichloroacetylations instead of trifluoro-
acetylations. The number of fluorines in each original
derivative was determined by its mass shift in the
trichloroacetylated form. In each case, the number of
fluorines matched those determined by elemental com-
position analysis. No other group of three masses was
consistent with each other and with the Ile7 angiotensin
III starting material. The ion of m/z 826 was not present
in the MALDI-FT-ICR spectrum at sufficient abundance
for an exact mass measurement; however, the mass and
fragmentation data from the MALDI-TOF-TOF spec-
trum, as well as the elemental composition assignment
of the other three masses of interest, strongly suggest
that the ion of m/z 826 is due to loss of the C-terminal Ile
from acetylated starting Ile7 angiotensin III. No ions
which could be attributed to loss of other residues in the
peptide were observed in this MALDI-TOF spectrum;
the loss of the C-terminal isoleucine residue seemed to
be specific.
An early observation was made that upon activation
by MALDI-TOF-TOF at 1 kV acceleration potential with
no collision gas added, some solution-phase [b(n1) 
OH  H]S
 ion structural analogs rearranged and frag-
mented into the [b(n2)  OH  H]
 product ion as
their most preferred fragmentation pathway (hereafter
termed “specific-fragmenting”). In contrast, the most
preferred fragmentation pathway for other solution-
phase [b(n1)  OH  H]S
 ion structural analogs were
into more standard b- or y-type ions, with the [b(n2) 
OH  H] fragment ion present but not representing
the most favored fragmentation pathway (hereafter
termed “nonspecific-fragmenting”). For example, the
MALDI-TOF-TOF MS/MS spectrum of the solution-
phase generated [b6  OH  H]S
 ion structural analog
of Ile7 angiotensin III (peptide sequence RVYIHPI) with
an N-terminal trifluoroacetylation and acetylation [Ac]
of the Tyr3 sidechain (m/z 922 and labeled as [b6  OH
 H  F3Ac  Ac] in Figure 1) obtained by unimolecu-
lar decomposition is shown in Figure 2a. The proton-ated molecule of the [b6  OH  H]S
 ion structural
analog of Ile7 angiotensin III (m/z 922.4) fragmented in a
specific manner, yielding primarily the [b5OHH]

ion of m/z 825.4, with the [b4 OHH]
 ion and some
standard a- and b-type ions present at relatively low
abundance. Similar fragmentation patterns for the
[b(n1)OHH]
 ion of angiotensin III and the [b(n1)
 OH  Na] ion of methionine enkephalin in MS3
experiments were previously reported by Thorne and
Gaskell, where the [b(n2)  OH  Cat]
 ion was the
only significant fragmentation product observed [19].
Under the same fragmentation conditions used for the
experiment above, the MS/MS spectrum of the proton-
ated molecule of full-length acetylated, trifluoroacety-
lated Ile7 angiotensin III (Figure 1, m/z 1035.6) yields
mainly b- and a-type fragment ions, with no detectable
[b5  OH  H]
 fragment product (data not shown).
The unimolecular decay MS/MS spectrum of the solu-
tion-phase generated [b4  OH  H]S
 ion structural
analog of proctolin (peptide sequence RYLPT, m/z
632.1), with an N-terminal acetylation and Tyr2
sidechain acetylation, is shown in Figure 2b. In contrast
to the MS/MS spectrum of the solution-phase gener-
ated [b(n1)  OH  H]S
 ion structural analog of Ile7
angiotensin III (m/z 922.4) shown in Figure 2a, the
fragmentation of this [b4OHH 2Ac]S
 ion analog
of proctolin yields [b3  OH  H]
 fragment ion of m/z
535.5 at a relative abundance of 47%, but the most
abundant fragment ion is a b2-NH3 ion, with many
other abundant b- and a-type ions present. This frag-
mentation pattern is quite similar to diacetylated full
length proctolin. Solution-phase generated [b(n1) 
OH  H]S
 ion structural analogs of proctolin frag-
mented in this nonspecific fashion regardless of acety-
lation or trifluoroacetylation in all cases examined (data
not shown).
In order to determine if the observed differences
between fragmentation pathways reported here, as well
as those previously reported [12, 19], are generally
applicable, we attempted to form the solution-phase
[b(n1)  OH  H]S
 ion structural analogs from a
variety of peptides. A list of the peptides which were
successfully derivatized is shown in Table 2. For the
peptides studied, two factors were determined to be
necessary for the successful formation and detection of
the solution-phase [b(n1)  OH  H]S
 ion structural
analog: first, the peptide must have a free acid C-
terminus; second, the peptide must have either a histi-
dine or arginine side chain. The need for a free acid
C-terminus has been previously reported for formation
of the gas-phase [b(n1)  OH  H]
 ion [12]. The need
for a histidine or arginine side chain is probably not
necessary for the chemistry; rather, due to the high
amount of acetylation that occurs under these reaction
conditions, a basic side chain that is resistant to acety-
lation is probably necessary for ionization in the posi-
tive mode. Peptide [b(n1)  OH  H]S
 ion structural
analogs that demonstrated a propensity to fragment
and rearrange to the [b(n2)  OH  H]
 ion in
612 SHARP AND TOMER J Am Soc Mass Spectrom 2005, 16, 607–621preference to any other product ion when fragmented
by MALDI-TOF-TOF at a 1 kV acceleration potential
with no collision gas added (as determined by the most
abundant product ion in the MS/MS spectra) were
labeled “specific” fragmenting. Peptide [b(n1)  OH 
H]S
 ion structural analogs that demonstrated a propen-
sity to preferentially fragment into a product ion other
than the [b(n2)  OH  H]
 ion when fragmented
Figure 2. (a) MALDI-TOF-TOF MS/MS spec
structural analog of N-terminally trifluoroacetyla
abundant fragment ion is the [b5  OH  H
spectrum of the solution-phase [b4  OH  H]S

[b3  OH  H]
 ion of m/z 535.5 is present, b
b2-NH3 ion of m/z 387.3.
Table 2. Fragmentation patterns of successfully-formed solution
Name S
LWMRFA LWMRFA
[Sar1, Gly8] angiotensin II Sar-RVY
[Sar1] angiotensin II Sar-RVY
angiotensin I DRVYIHP
[Val5] angiotensin I DRVYVH
[Ile7] angiotensin III RVYIHPI
Proctolin RYLPT
Neurotensin pyroGlu-
HPFHLDLVY HPFHLDL
PHPFHLFVY PHPFHLF
Bradykinin RPPGFSP
des-Arg1-bradykinin PPGFSPF
9des-Arg -bradykinin RPPGFSPFunder the same conditions were labeled “nonspecific”
fragmenting. By separating the [b(n1)  OH  H]S
 ion
structural analogs based on their most preferred frag-
mentation pathway, the structures of the peptides can
be examined for features that promote further rear-
rangement of the [b(n1)  OH  H]
 ion into the
[b(n2)  OH  H]
 ion. No immediately obvious
structural correlations were observed between the spe-
of the solution-phase [b6  OH  H]S
 ion
tyrosine acetylated Ile7 angiotensin III. The most
n of m/z 825.4. (b) MALDI-TOF-TOF MS/MS
structural analog of diacetylated proctolin. The
e most abundant fragmentation product is the
se [b(n1)OH  H]
s ion structural analogs
nce Fragmentation pattern
Specific
Specific
Specific
Specific
Specific
Specific
Nonspecific
KPRRPYIL Nonspecific
Nonspecific
Nonspecific
Nonspecific
Nonspecifictrum
ted,
] io
ion
ut th-pha
eque
IHPG
IHPF
FHL
PFHL
LYEN
VY
VY
FR
RNonspecific
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fragmenting peptides contained at least one arginine,
but this observation could be coincidence, because of
the low number of histidine-containing, arginine-free
peptides examined. A peptide with an N-terminal sec-
ondary amine was found in both the specific-fragment-
ing (N-terminal sarcosine) and the nonspecific-frag-
menting (N-terminal pyroglutamate) peptides. Both
categories had peptides with N-terminal arginines, but
neither required an N-terminal arginine. Other than the
two previously-mentioned requirements, no conclu-
sions could be reached from this tabulation.
To this point, the exact mass measurement and
MS/MS fragmentation data suggest that we are repro-
ducing the [b(n1)  OH  H]
 ion structure by
solution-phase chemistry to form an exact structural
analog to the gas-phase rearrangement and fragmenta-
tion product; however, a more direct correlation be-
tween the structure of the solution-phase generated
[b(n1)  OH  H]S
 ion structural analog and the
gas-phase [b(n1)  OH  H]
 rearrangement and
fragmentation product ion must be established before
the analog can be used as a model of gas-phase [b(n1)
 OH  H] ion structure. In order to do so, the
MS/MS spectra of the gas-phase [b(n1)  OH  H]

rearrangement and fragmentation product ion, the so-
lution-phase generated [b(n1)  OH  H]S
 ion struc-
tural analog, and a C-terminally truncated peptide with
the same sequence were compared. Figure 3 shows a
comparison between the fragmentation spectra of the
gas-phase [b8 OHH]
 rearrangement fragment ion
formed by MS/MS of diacetylated bradykinin (peptide
sequence RPPGFSPFR, Figure 3a), the solution-phase
diacetylated [b8  OH  H]S
 ion structural analog
formed from bradykinin by the solution-phase chemis-
try described above (Figure 3b), and the diacetylated
des-Arg9-bradykinin truncated peptide (Figure 3c). Fig-
ure 3a shows the MS/MS/MS spectrum of diacetylated
bradykinin. For analysis of the structure of the gas-
phase generated [b(n1)  OH  H]
 ion of bradykinin,
the singly-protonated molecule of diacetylated brady-
kinin was initially fragmented in the QIT, and the [b8 
OH  H] fragment ion of m/z 988 was isolated and
fragmented in an MS/MS/MS experiment at a collision
potential of 1.8 V. The most abundant fragment ion
observed in the MS3 spectrum is the y7 ion; the [b7 
OH  H] ion of m/z 841 is also detected, but at
significantly lower relative abundance (25%). Figure
3b shows the MS/MS spectrum of the diacetylated
solution-phase [b8  OH  H]S
 bradykinin structural
analog acquired at a collision potential of 1.8 V. The
product ion spectrum is virtually identical to that of the
gas-phase formed [b8  OH  H]
 ion (Fig 3a), with the
y7 fragment ion the most abundant fragment ion de-
tected. Comparison of the two fragmentation spectra
strongly supports the proposition that the solution-
phase formed [b8  OH  H]S
 ion structural analog is
structurally identical to the gas-phase formed [b8  OH
 H] ion. Figure 3c shows the MS/MS spectrum ofdiacetylated des-Arg9-bradykinin acquired at a collision
potential of 1.8 V. The product ion spectrum of the
truncated peptide is virtually identical to the spectra of
the gas-phase [b8  OH  H]
 ion and the solution-
phase formed [b8  OH  H]S
 ion structural analog,
with the y7 fragment ion as the base peak, and various
b- and y-type ions present at lower abundance. Product
ions resulting from a loss of 60 Da from the protonated
molecule or from a fragment ion are also present at
considerable abundance in the fragmentation spectra of
all three peptides. Close examination of the fragmenta-
tion spectra reveal that all fragment ions that demon-
strate the 60 Da loss contain Ser6, which is known to be
acetylated. In addition, no appreciable loss of 18 Da
(H2O) or 42 Da (HN  C  NH) from the protonated
molecule is detected, and no carboxylic acid group is
adjacent to an arginine to allow for the previously-
described loss of the arginine side chain [15, 28]. These
observations lead to the assignment of the 60 Da losses
to be loss of acetic acid from the Ser6 side chain. The
identical fragmentation spectra of the solution-phase
diacetylated [b8  OH  H]S
 ion structural analog of
bradykinin, the gas-phase [b8  OH  H]
 fragment
ion of diacetylated bradykinin, and the diacetylated
des-Arg9-bradykinin support the hypothesis that the
structure of [b(n1)  OH  H]
 ions is identical to that
of the truncated peptide [12, 13, 17]. The observation
that the gas-phase formed [b8  OH  H]
 ion frag-
ments similarly to the truncated des-Arg9-bradykinin
was reported previously, and was one of the key points
in proposing that the structure of the [b(n1)  OH 
H]  ion has a free C-terminal carboxylic acid [12].
In addition to bradykinin, the MS/MS spectra of the
gas-phase [b9  OH  H]
 rearrangement and frag-
mentation product ion formed from diacetylated angio-
tensin I (peptide sequence DRVYIHPFHL) by MS/MS,
the solution-phase diacetylated [b9  OH  H]S
 ion
structural analog formed from angiotensin I by the
solution-phase chemistry described above, and a C-
terminally truncated diacetylated angiotensin I peptide
were compared. The MS/MS/MS spectrum of diacety-
lated angiotensin I is shown in Figure 4a. Diacetylated
angiotensin I was fragmented by CAD, and the [b9 
OH  H] fragment ion (m/z 1267.7) was isolated and
fragmented at an activation energy of 1.8 V. The most
abundant product ion observed is the [b8  OH  H]

ion of m/z 1130, similar to that observed in the MS/MS
spectrum of the solution-phase formed [b6 OHH]S

ion structural analog of Ile7 angiotensin III, m/z 922.4
(Figure 2a). Figure 4b shows the MS/MS spectrum of
the solution-phase [b9  OH  H]S
 ion structural
analog of diacetylated angiotensin I (m/z 1267.7) ac-
quired at a collision energy of 1.8 V. The product ion
spectrum is almost identical to that of the gas-phase
formed [b9  OH  H]
 ion shown in Figure 4a, again
strongly suggesting that the structure of the gas-phase
formed [b(n1)  OH  H]
 ion and the solution-phase
[b(n1)  OH  H]S
 ion structural analog are identical.
Figure 4c shows the MS/MS spectrum of diacetylated
rum
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1.8 V. The most abundant fragment in this spectrum is
the loss of 60 Da. This 60 Da loss is accompanied by
losses of 18 Da (H2O) and 42 Da (HN  C  NH, ion
marked with an asterisk), indicative of a side-chain loss
from the N-terminal Asp and Arg side chains, similar to
the side chain losses frequently observed for C-terminal
arginine-containing peptides [15, 28]. This fragment ion
resulting from the loss of 60 Da is present at less than
5% relative abundance in the gas-phase [b9  OH 
H] ion and solution-phase [b9  OH  H]S
 ion
structural analog fragmentation spectra, indicating that
the truncated peptide has a different primary fragmen-
Figure 3. (a) ESI-QIT MS/MS/MS spectrum o
diacetylated bradykinin. (b) ESI-QIT MS/MS spe
OH  H]S
 ion structural analog of bradykin
des-Arg9-bradykinin. The most abundant fragm
arginine of m/z 790, similar to the MS/MS specttation pathway than the [b9  OH  H]
 ion. Thesedata strongly suggest that, in at least the case of
diacetylated angiotensin I, the structure of the [b(n1) 
OH  H] ion is not the same as that of the truncated
peptide.
In order to further characterize the solution-phase
[b(n1)OHH]S
 ion structural analog and gas-phase
formed [b(n1)  OH  H]
 ion, we examined the
energy of fragmentation for each ion by tandem mass
spectrometry in a quadrupole ion trap. In this experi-
ment, the ion of interest was fragmented by MS/MS at
different activation voltages, and the ratio of the abun-
dance of fragment ions divided by the total ion abun-
dance was calculated and averaged over one minute.
cetylated bradykinin¡[b8  OH  H]
 ion of
of solution-phase generated diacetylated [b8
c) ESI-QIT MS/MS spectrum of diacetylated
n each spectrum is the loss of the N-terminal
of full length diacetylated bradykinin.f dia
ctrum
in. (
ent iWhen plotted this way, the data yield a sigmoidal plot,
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find the inflection point situated halfway between the
minimum (only parent ion present, with no fragment
ion signal above the noise) and the maximum (only
fragment ions present, no parent ion signal above the
noise). This inflection point, V50, can be compared
between species using the same laboratory frame of
reference to determine the ease at which an ion frag-
ments. Ions with identical structures will have an iden-
tical V50, while ions with different structures will prob-
ably have a different V50. In addition, the V50 will
indicate which ions are more susceptible to fragmenta-
Figure 4. (a) ESI-QIT MS/MS/MS spectrum of
diacetylated angiotensin I. (b) ESI-QIT MS/MS s
 OH  H]S
 ion structural analog of angioten
des-Leu10-angiotensin I. The MS/MS spectra of t
solution-phase generated structural analog are id
peptide is different.tion [29]. As the MS/MS experiments were performedin a quadrupole ion trap, all MS/MS fragmentations
were a result of multiple low-energy collisions; there-
fore, accuracy in determining the V50 value was ob-
tained by careful control of the MS/MS parameters and
acquisition of multiple spectra over the one minute time
frame. For analysis of the gas-phase generated [b(n1) 
OH  H] ions, the [b(n1)  OH  H]
 rearrangement
and fragmentation product was initially formed by
MS/MS in the QIT at a fixed voltage, followed by
collisional cooling of the product ion in the high-
pressure QIT and isolation of the [b(n1)  OH  H]

ion for MS3 analysis.
tylated angiotensin I¡ [b9  OH  H]
 ion of
um of solution-phase generated diacetylated [b9
. (c) ESI-QIT MS/MS spectrum of diacetylated
s-phase generated [b9  OH  H]
 ion and the
al, while the MS/MS spectrum of the truncateddiace
pectr
sin I
he ga
enticFigure 5a shows the fragmentation energy plot for
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 ions struc-
tural analog of diacetylated bradykinin (peptide se-
quence RPPGFSPFR, m/z 988.5), gas-phase generated
[b8  OH  H]
 ions of diacetylated bradykinin (m/z
988.5), and truncated diacetylated des-Arg9-bradykinin
(m/z 988.5). The three plots are virtually identical, with
V50 values of 1.28  0.01 V and very similar curve
Figure 5. (a) V50 plot of the fragmentation efficiency by ESI-QIT
MSn of the diacetylated solution-phase generated [b8 OHH]S

ion structural analog of bradykinin versus the diacetylated gas-
phase generated [b8  OH  H]
 ion of bradykinin vs. the
diacetylated truncated des-Arg9-bradykinin. (b) V50 plot of the
fragmentation efficiency by ESI-QIT MSn of the diacetylated
solution-phase generated [b9 OHH]S
 ion structural analog of
angiotensin I vs. the diacetylated gas-phase generated [b9 OH
H] ion of angiotensin I vs. the diacetylated truncated des-Leu10-
angiotensin I. The V50 plots for bradykinin are all superimposable;
for angiotensin I, the V50 plot for the gas-phase generated [b9 
OH  H] ion and the solution-phase generated structural analog
are identical, while the truncated angiotensin I fragments signifi-
cantly more readily.shapes between the three species. These data stronglysuggest that the structures of the gas-phase generated
and solution-phase generated [b8  OH  H]
 ions are
identical to the structure of the truncated des-Arg9-
bradykinin (i.e., loss of the C-terminal arginine and a
free C-terminal carboxylic acid), which is in agreement
with the MS/MS fragmentation spectra presented in
Figure 3.
Figure 5b shows the fragmentation energy plot for
solution-phase generated [b9  OH  H]S
 ion struc-
tural analogs of diacetylated angiotensin I (peptide
sequence DRVYIHPFHL), gas-phase generated [b9 
OH  H] ions of diacetylated angiotensin I, and
truncated diacetylated des-Leu10-angiotensin I. The
plots of solution-phase [b9  OH  H]S
 ion structural
analogs and gas-phase generated [b9  OH  H]
 ions
are almost superimposable, with a V50 of 1.64  0.01 V
and virtually identical curve shapes. However, the plot
of truncated des-Leu10angiotensin I is significantly dif-
ferent from those of the gas-phase generated [b9  OH
 H] ions and solution-phase [b9  OH  H]
 ion
structural analogs, with a V50 significantly lower (V50 
1.59). Due to the large number of spectra acquired,
statistical analysis is difficult. One point chosen at
random (des-Leu10angiotensin I at 1.65 V) was ana-
lyzed for statistical error, and was found to have a
standard deviation of0.010. These results agree nicely
with the previous MS/MS spectra, which show the
truncated diacetylated des-Leu10-angiotensin I readily
losing 60 Da from the amino acid side chains of arginine
and aspartate (Fig 4c) while the gas-phase [b9  OH 
H] ions and solution-phase generated [b9OHH]

ion structural analogs fragmented primarily into the [b8
 OH  H] ion (Fig 4a-b). Combined with the MS/MS
fragmentation pattern data, these results demonstrate
that the structures of the [b9  OH  H]
 ion and the
[b9  OH  H]S
 ion structural analog of diacetylated
angiotensin I is not the same as the diacetylated trun-
cated des-Leu10-angiotensin I. Higher energy MS/MS
fragmentation experiments yielded sufficient fragment
ions to show that the sites of acetylation of the diacety-
lated gas-phase [b9  OH  H]
 ions, the diacetylated
solution-phase [b9  OH  H]S
 ion structural analogs,
and the diacetylated truncated des-Leu10-angiotensin I
all occurred at the same locations (N-terminus and
Tyr4); therefore, the structural difference almost cer-
tainly involves the C-terminus.
Previous MS/MS/MS experiments examining di-
acetylated angiotensin I found that the primary frag-
mentation pathway of the [b9  OH  H]
 ion was loss
of the C-terminal residue, resulting in the [b8  OH 
H]  ion (Figure 4a). In order to test if this trend was
observed with other specific-fragmenting peptides, we
performed MSn experiments on both solution-phase [b6
 OH  H]S
 ion structural analogs and gas-phase
formed [b6  OH  H]
 ions of trifluoroacetylated Ile7
angiotensin III (peptide sequence RVYIHPI, m/z 880.4).
Figure 6a shows the MSn spectra of trifluoroacetylated
Ile7 angiotensin III. The top panel is the MS3 experi-
ment; the base peak in this experiment is actually the
4 O
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attributable to the additional loss of water from the
[b5  OH  H]
 ion due to the characteristic nature
of CAD in a quadrupole ion trap (multiple accelera-
tion and deceleration events occurring over 40 ms in
the presence of relatively high pressure helium), as
fragmentation of the [b6  OH  H]S
 ion structural
analogs by CAD on an ESI-Q-TOF hybrid instrument
or by unimolecular decomposition on a MALDI-TOF-
TOF instrument yield primarily the [b5  OH  H]

ion (data not shown).
The middle panel shows the MS4 experiment, where
the [b5  OH  H]
 ion was isolated and fragmented.
In this spectrum, the primary fragmentation product is
the [b4 OHH]
 ion, although the overall signal has
decreased due to ion loss in the MSn process. In the
bottom panel, an MS5 experiment is shown, where the
[b4  OH  H]
 ion is isolated and fragmented. The
Figure 6. (a) ESI-QIT MSn study of the fragme
the gas-phase generated [b6  OH  H]
 ion of
The top panel shows the fragmentation pattern
experiment; the middle panel shows the fragmen
in an MS4 experiment, and the bottom panel sho
ion of m/z 646 in an MS5 experiment. (b) ESI-QIT
 OH  H] ions of the solution-phase gen
N-terminally trifluoroacetylated Ile7 angiotensin
the [b6  OH  H]S
 ion structural analog of m/
the fragmentation pattern of the [b5 OHH]

panel shows the fragmentation pattern of the [bprimary product ion is the [b3  OH  H]
 ion,although there is very little overall signal. No further
fragmentation could be accomplished due to a lack of
signal in the MS6 spectrum. Figure 6b shows an analo-
gous experiment performed on the [b6  OH  H]S
 ion
structural analog of trifluoroacetylated Ile7 angiotensin
III. The top panel shows the MS/MS spectrum of the [b6
 OH  H]S
 ion structural analog. Again, the most
abundant fragment ion is the b5 ion due to the multiple
collision mechanism of fragmentation in the QIT. The
middle panel shows the MS3 spectrum, where the [b5
OH  H] ion was isolated and fragmented. The [b4 
OH  H] ion is the most abundant product of this
fragmentation event. The bottom panel shows the MS4
spectrum, where the [b4  OH  H]
 ion was isolated
and fragmented. Again, the peptide loses the C-termi-
nal residue, retaining the C-terminal OH to form the [b3
 OH  H] ion. These data show that the specific-
fragmentation occurs in an iterative fashion; therefore,
n properties of the [b(nx)  OH  H]
 ions of
rminally trifluoroacetylated Ile7 angiotensin III.
he [b6  OH  H]
 ion of m/z 880 in an MS3
n pattern of the [b5  OH  H]
 ion of m/z 783
e fragmentation pattern of the [b4  OH  H]

study of the fragmentation properties of [b(nx)
d [b6  OH  H]S
 ion structural analog of
he top panel shows the fragmentation pattern of
in an MS2 experiment; the middle panel shows
f m/z 783 in an MS3 experiment, and the bottom
H  H] ion of m/z 646 in an MS4 experiment.ntatio
N-te
of t
tatio
ws th
MSn
erate
III. T
z 880
ion othe structure that promotes this specific-fragmentation
heme
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 ion is probably retained in
subsequent fragmentation and rearrangement events.
The nature of the chemistry itself for creating these
solution-phase [b(n1)  OH  H]S
 ion structural
analogs suggests certain ideas. The fact that these ions
are generated in a reaction known to promote anhy-
dride formation [24, 30] supports recent theoretical
calculations that suggest that [b(n1)  OH  H]
 and
[b(n1)  OH  Cat]
 ions go through an anhydride
intermediate [16, 17]. However, all mechanisms for
formation of [b(n1)  OH  H]
 ions of which the
authors are aware present a structure that is identical to
the truncated peptide [12, 13, 16, 17]. Our results with
using bradykinin, as well as by the work previously
reported for bradykinin [22] support this structure for
the [b(n1) OHH]
 fragment ions; however, results
for angiotensin I reported here directly refute this
structure for these fragment ions. At least two different
structures exist for [b(n1)  OH  H]
 fragment ions,
requiring different mechanisms of rearrangement and
fragmentation.
One potential mechanism, based on the results pre-
sented here and the work reported by Farrugia and
O’Hair on the fragmentation of arginine-containing
dipeptides, [17] is proposed in Scheme 3. The portions
that are marked with the heavy dashed lines are pro-
posed for the specific-fragmenting peptides, while the
portions of the mechanism represented by the dotted
lines are consistent with the mechanisms previously
reported [12, 13, 17] and consistent with the data
reported here for nonspecific-fragmenting peptides.
The portions of the mechanism represented by solid
lines are shared between the two pathways. The pro-
Scposed difference in the mechanisms of rearrangementand fragmentation between the specific-fragmenting
peptides and the nonspecific-fragmenting peptides
hinge upon which carbonyl oxygen attacks the amine
hydrogen at the C-terminal end of the peptide anhy-
dride. For the specific-fragmenting peptides, the domi-
nant rearrangement pathway results in a [b(n1)  OH
 H] ion that retains the linear anhydride structure.
This retention of the linear anhydride structure pro-
motes further fragmentation into the [b(n2)  OH 
H] ion upon subsequent activation events due to the
fewer steps in the rearrangement process. For nonspe-
cific-fragmenting peptides, the dominant fragmentation
pathway results in a structure that is identical to the
truncated peptide, making the formation of the [b(n2)
 OH  H] less likely, but still possible.
In order to determine if the structure proposed in
Scheme 3 for the specific-fragmenting [b(n1)  OH 
H] ion is feasible, electron capture dissociation (ECD)
was performed on the solution-phase formed, specific-
fragmenting acetylated, trifluoroacetylated [b6  OH 
2H]S
2 ion structural analog of Ile7 angiotensin III (pep-
tide sequence RVYIHPI, m/z 922.5). ECD is a very rapid,
nonergodic dissociation method [26]; therefore, the ex-
tensive rearrangements that occur during ergodic
MS/MS processes (IRMPD, CAD) should not dominate
the tandem mass spectrum, and more reliable informa-
tion about the structure of the peptide should be
obtainable. The ECD product spectrum for the solution-
phase formed [b6  OH  2H  F3Ac  Ac]S
2 ion
structural analog is shown in Figure 7. The fragments
shown are consistent with the proposed structure for
the specific-fragmenting [b(n1)  OH  H]
 ion;
however, the fragments do not rule out other structures
3for the C-terminus. The fragmentation pattern does
SI.
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fragments from all along the backbone can be detected,
showing that the structural differences must be at the
C-terminus. The voltage used for generation of the
electrons is near the border between traditional ECD
and “hot” electron capture dissociation [31, 32], explain-
ing the abundant secondary fragmentation ions result-
ing in the cleavage of almost every covalent bond along
the backbone. Unfortunately, no bonds at the C-termi-
nus were cleaved, preventing us from confirming or
eliminating from consideration the structure for the
[b(n1)  OH  H]
 ion presented in Scheme 3.
Conclusions
The results of this study have led to a new tool in the
study of the structure and properties of [b(n1)  OH 
H] ions, as well as a greater understanding of the
nature of these ions. The data presented here have
shown that solution-phase chemistry can generate pep-
tide derivatives that are identical to gas-phase gener-
ated [b(n1)OHH]
 ions. This discovery allows the
Figure 7. A comparison of the proposed struct
acetylated [b6 OHH]S
 ion structural analog
of the solution-phase generated [b6  OH  2H
acetylated, trifluoroacetylated Ile7 angiotensin IIresearcher to bring an enormous array of analyticaltechniques to bear on the question of the structure and
properties of the [b(n1)  OH  H]S
 ion structural
analog. Current efforts at purifying a solution-phase
[b(n1)  OH  H]S
 ion structural analog of a specific-
fragmenting peptide for analysis by NMR spectroscopy
are underway. The results presented above show that at
least two different structures exist for the [b(n1)  OH
 H] ion. One of these structures is probably identical
to that of the corresponding truncated peptide (i.e., a
free acid C-terminus). The other structure is clearly
different. MS/MS fragmentation studies of [b(n1) 
OH  H] ions and their structural analogs that frag-
ment identically to the truncated peptide show a frag-
mentation spectrum that does not particularly favor the
formation of the [b(n2)  OH  H]
 ion, while frag-
mentation studies of [b(n1)  OH  H]
 ions and their
structural analogs that do not fragment identically to
the truncated peptide show a fragmentation spectrum
that does favor the formation of the [b(n2) OHH]

ion. Analysis of the primary sequence of peptides in
both groups failed to find any single structural feature
that was common to only one group. Both the MS/MS
f the specific-fragmenting acetylated, trifluoro-
7 angiotensin III and the ECD product spectrum
n structural analog of the specific-fragmentingure o
of Ile
]2 iofragmentation patterns and the measured V50 energy of
620 SHARP AND TOMER J Am Soc Mass Spectrom 2005, 16, 607–621fragmentation show that one of these structures is
almost certainly a free C-terminal carboxylic acid, iden-
tical to the truncated peptide. The other structure iden-
tified in this study is clearly different from the truncated
peptide; however, the exact nature of this difference has
not yet been determined. The observation that a struc-
tural analog which fragments identically to the [b(n1)
OH  H] ion can be formed by chemical derivatiza-
tion suggests that the structure of the [b(n1)  OH 
H] ion is not due to an intramolecular interaction
within the peptide, but rather is due to a change in the
covalently-bound structure. In addition, electron cap-
ture dissociation is known to usually preserve stable
noncovalent bonds due to the nonergodic nature of the
dissociation; therefore, the ECD experiment showed
that the structural difference between specific-frag-
menting [b(n1)  OH  H]
 ions and the truncated
peptide almost certainly occurs at the C-terminus. A
potential mechanism for the formation of [b(n1)  OH
 H] ions has been presented; however, much more
research must be performed before any mechanism for
these rearrangement reactions can be relied upon with
confidence. Examination of the structural differences
between specific-fragmenting and nonspecific-frag-
menting peptides (Table 2) does not yield any obvious
structural causes for the differences in the dominant
fragmentation pathway for each respective [b(n1) 
OH  H] ion. More study is required to determine
why certain [b(n1)  OH  H]
 ions fragment in a
primarily specific fashion, while others fragment pri-
marily nonspecifically. Continuing characterization of
the solution-phase [b(n1)  OH  H]S
 ion structural
analog using a variety of solution-phase analytical
techniques such as NMR and FT-IR spectroscopy will
allow the elucidation of the structure(s) of the [b(n1) 
OH  H]S
 ion structural analog, which will greatly aid
in the development of an accurate mechanism of
formation.
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